Worth reading
32Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
3815
Millions of yen (year-on-year increase in revenue)Wording
Conditional
How definitive the wording is.Contents of this document
Earnings presentationCumulative second quarter of the fiscal year ending December 2026 (January–June)5 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥18,910 million
Operating profit¥1,881 million
Net income¥1,591 million
Selling, general and administrative expenses¥6,953 million
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Increase in the number of milestones achieved (from 5 to 8)
- Year-on-year increase in revenue¥3,815 million
- Decrease in R&D expenses¥1,474 million
- Decrease in selling, general and administrative expenses¥612 million
New initiatives
- Licensing agreement with サンセラ・ファーマシューティカルズ・ホールディング for vamorolone in Japan, South Korea, Australia and New Zealand
- Obtained marketing approval for QUVIVIQ in Taiwan, with a launch planned during 2026
- Licensing agreement for a GPCR-targeted program with a newly established European venture company
- Acquisition of shares in the same venture company and participation in its Series A financing
Key KPIsA metric the company considers important as a management benchmark.
- Number of milestones achieved8 EngagementsYear on year against the same period last year5 milestones in the same period of the previous year
- Number of development programsMore than 30
Number of stores and locations
6 major sites. Number of openings and closures during the period: Not disclosedNumber of employees
Headcount, changes during the period and hiring plans: Not disclosed| Item | Details |
|---|---|
| Document type | Earnings presentation |
| Fiscal Period Covered | Cumulative second quarter of the fiscal year ending December 2026 (January–June) |
| Net Sales | ¥18,910 million |
| Operating profit | ¥1,881 million |
| Net income | ¥1,591 million |
| Selling, general and administrative expenses | ¥6,953 million |
| Breakdown of Factors Affecting the Change | Factors Increase in the number of milestones achieved (from 5 to 8) / Amount Not disclosed, Factors Year-on-year increase in revenue / Amount ¥3,815 million, Factors Decrease in R&D expenses / Amount ¥1,474 million, Factors Decrease in selling, general and administrative expenses / Amount ¥612 million |
| Key KPIs | Indicator name Number of milestones achieved / Value 8 Engagements / Year on year against the same period last year 5 milestones in the same period of the previous year, Indicator name Number of development programs / Value More than 30 / Year on year against the same period last year Not disclosed |
| Number of stores and locations | 6 major sites. Number of openings and closures during the period: Not disclosed |
| Number of employees | Headcount, changes during the period and hiring plans: Not disclosed |
| New initiatives | Licensing agreement with サンセラ・ファーマシューティカルズ・ホールディング for vamorolone in Japan, South Korea, Australia and New Zealand, Obtained marketing approval for QUVIVIQ in Taiwan, with a launch planned during 2026, Licensing agreement for a GPCR-targeted program with a newly established European venture company, Acquisition of shares in the same venture company and participation in its Series A financing |
Items this document does not state (20)
Ordinary incomeGross Profit MarginOperating profit marginResults for the three months of the current quarterFull-year earnings forecastProgress against full-year forecastSelf-assessment against the planSegment resultsUnit price and quantity metricsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The increase in revenue was mainly attributable to the achievement of 8 milestones in the interim period, compared with 5 in the same period of the previous year. Research and development expenses decreased as multiple clinical development programs progressed and the company narrowed its R&D focus, while selling, general and administrative expenses declined as a result of cost-reduction initiatives.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.